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Extensive and Prolonged Restoration of Dystrophin
Expression with Vivo-Morpholino-Mediated Multiple
Exon Skipping in Dystrophic Dogs
Toshifumi Yokota,1–3 Akinori Nakamura,3,4 Tetsuya Nagata,3 Takashi Saito,3,5
Masanori Kobayashi,3,6 Yoshitsugu Aoki,3 Yusuke Echigoya,1
Terence Partridge,7,8 Eric P. Hoffman,7,8 and Shin’ichi Takeda 3

Duchenne muscular dystrophy (DMD) is a severe and the most prevalent form of muscular dystrophy, characterized by rapid progression of muscle degeneration. Antisense-mediated exon skipping is currently one of the
most promising therapeutic options for DMD. However, unmodified antisense oligos such as morpholinos
require frequent (weekly or bi-weekly) injections. Recently, new generation morpholinos such as vivomorpholinos are reported to lead to extensive and prolonged dystrophin expression in the dystrophic mdx
mouse, an animal model of DMD. The vivo-morpholino contains a cell-penetrating moiety, octa-guanidine
dendrimer. Here, we sought to test the efficacy of multiple exon skipping of exons 6–8 with vivo-morpholinos in
the canine X-linked muscular dystrophy, which harbors a splice site mutation at the boundary of intron 6 and
exon 7. We designed and optimized novel antisense cocktail sequences and combinations for exon 8 skipping
and demonstrated effective exon skipping in dystrophic dogs in vivo. Intramuscular injections with newly
designed cocktail oligos led to high levels of dystrophin expression, with some samples similar to wild-type
levels. This is the first report of successful rescue of dystrophin expression with morpholino conjugates in
dystrophic dogs. Our results show the potential of phosphorodiamidate morpholino oligomer conjugates as
therapeutic agents for DMD.

Introduction

D

uchenne muscular dystrophy (DMD) is a lethal and
the most common form of muscular dystrophy worldwide, which affects 1 in 3,500 boys (Duchenne, 1867; Zellweger and Antonik, 1975). There is currently no effective cure
for DMD. Most patients die in their 20s–30s with respiratory
or heart failure. DMD and its milder form, Becker muscular
dystrophy, are caused by mutations in the dystrophin (DMD)
gene (Hoffman et al., 1987; Koenig et al., 1987). Antisense
oligonucleotide-mediated exon skipping therapy is a most
promising approach to curing DMD (Pramono et al., 1996;

Dunckley et al., 1998; Goyenvalle et al., 2011; Lu et al., 2011).
Antisense oligos such as phosphorodiamidate morpholino
oligomers (PMOs, or morpholinos) and 2’O- methyl antisense
oligos with phosphorothioate bonds (2’OMePS) against dystrophin mRNA lead to the production of internally deleted inframe transcripts both in vitro and in vivo (Pramono et al.,
1996; Dunckley et al., 1998; Lu et al., 2005; Yokota et al., 2009a;
Yokota et al., 2012). The truncated quasi-dystrophin retains
some functions like mild Becker dystrophy or even leads to
asymptomatic individuals in some cases (Beroud et al., 2006;
Nakamura et al., 2008; Aoki et al., 2010; Goyenvalle et al.,
2010). Exon skipping therapies with PMO or 2’OMePS
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antisense oligos targeting the exon 51 are currently under
phase-2/3 clinical trials (Aartsma-Rus and van Ommen, 2007;
van Deutekom et al., 2007; Kinali et al., 2009; Cirak et al., 2011;
Goemans et al., 2011).
One of the biggest challenges of exon-skipping therapy is that
the single exon skipping is applicable to only approximately
50% of DMD patients (total of each single individual target
exon). In contrast, double or multiple exon skipping is potentially applicable to 90% of patients (Aartsma-Rus et al., 2006;
Yokota et al., 2007a). The dystrophic dog requires more than
one exon skipping (multiple exon skipping targeting exon 6 and
exon 8 in the dystrophin mRNA). Previously we reported the
first successful multiple (double) exon-skipping treatment in
body-wide skeletal muscles in Canine X-linked muscular dystrophy (CXMD) with a cocktail of antisense phosphorodiamidate morpholino oligomers (PMOs, morpholinos) (Yokota et al.,
2009a). The dog trial targeting exon 6 and exon 8 of dystrophin
mRNA led to 27% normal levels of dystrophin expression in
body-wide skeletal muscles detected by western blotting analysis on average. However, unmodified morpholinos exhibit
inefficient long-term delivery. The half-life of dystrophin expression was approximately 1–2 months (Wu et al., 2010).
Recently, new generation morpholinos such as cellpenetrating peptide conjugated phosphorodiamidate morpholino oligomers (PPMOs) and vivo-morpholinos (vPMOs)
were reported to induce prolonged and extensive rescue of
dystrophin expression and ameliorate the function in cardiac
muscles in dystrophic mdx mice (Wu et al., 2009; Goyenvalle
et al., 2010; Jearawiriyapaisarn et al., 2010; Crisp et al., 2011;
Widrick et al., 2011; Wu et al., 2011a). vPMOs are morpholino
oligomers conjugated with delivery moiety containing eight
terminal guanidinium groups on a dendrimer scaffold
that enable entry into cells (Fig. 1A) (Morcos et al., 2008).
New generation morpholinos are efficiently delivered into
various tissues including muscle fibers in vivo (Wu et al.,
2009). Vivo-morpholino-mediated splice modulation efficiently also rescued Fukuyama congenital muscular dystrophy model mice and primary myotubes from human patients
(Taniguchi-Ikeda et al., 2011). Their delivery efficacy is reported to be more than 50 times higher than unmodified
morpholinos (Wu et al., 2009).
In this study, we focused on 2 aims. First, we employed a
novel backbone (vivo-morpholino) for the antisense therapy in
the dog model. Second, we tested novel antisense oligo cocktails designed for multiple exon skipping (exons 6 and 8) in the
canine DMD gene. We hypothesized that (1) vivo-morpholinos induce extensive and prolonged dystrophin expression in
dystrophic dogs, and (2) our novel antisense oligo cocktail can
improve the efficacy of exon 6–8 multiple skipping. We tested
these hypotheses and the efficacy of multiple (double) exon
skipping in dystrophic dogs in vivo. Vivo-morpholinos with
newly optimized sequences induced near normal level of
dystrophin protein and prolonged expression recovery.

study. We obtained consent from all of the owners of the dogs
involved in this study (All dogs are owned by NCNP).

Materials and Methods

Immunohistochemical analysis

Ethics Statement
All animal works have been conducted according to relevant national and international guidelines. The Experimental
Animal Care and Use Committee of the National Institute of
Neuroscience, National Center of Neurology and Psychiatry
(NCNP) Japan approved all experimental protocols in this

Animals
The CXMD dog is the beagle dog model of DMD (Shimatsu
et al., 2003). They were allowed ad libitum access to food and
drinking water. Dogs carrying mutations were identified by
reverse-transcription polymerase chain reaction (RT-PCR)
analysis as previously described (Sharp et al., 1992). Three- to
five-month-old dogs were used. Five dystrophic dogs were
used for injections. Four dystrophic dogs and three wild-type
dogs were used as non-treated controls. Animals were euthanized by exsanguination under general anesthesia.
Antisense oligos
Antisense oligos for targeted skipping of exons 6 and exon
8 in the canine DMD gene were used as previously described
(Tables 1, 2) (Yokota et al., 2009a; Saito et al., 2010). All PMOs
and vPMOs were obtained from Gene-tools, Inc (Morcos
et al., 2008). As control oligos, we employed Ex6A only
(GTTGATTGTCGGACCCAGCTCAGG) or 3-oligo cocktail
containing Ex6A (GTTGATTGTCGGACCCAGCTCAGG),
Ex6B (ACCTATGACTGTGGATGAGAGCGTT), and Ex8A
(CTTCCTGGATGGCTTCAATGCTCAC) for intramuscular
injections as indicated. The dose selection is based on previous
mouse studies with PMOs and vPMOs, showing that vPMOs
induce more than 10 · higher efficacy, and dog studies with
PMOs (Wu et al., 2009). The Ex8G dose and ratio were determined based on previous cell experiments (Saito et al., 2010).
Injections
Animals were anesthetized with thiopental sodium induction and maintained by isoflurane (Nacalai Tesque, Inc.) for all
intramuscular injections and muscle biopsies. General anesthesia was maintained with isoflurane administered through
an endotracheal tube. Skin was excised over the site of injection, muscle exposed, and the injection site marked with a
suture in the muscle. Antisense oligonucleotides were delivered by intramuscular injection using 1 mL saline bolus into
indicated skeletal muscles using a 27-gauge needle. Antisense
oligonucleotides were delivered as a singular or in mixtures as
previously described (Yokota et al., 2011). Tibialis anterior,
extensor digitorum longus, extensor carpi ulnaris, flexor digitorum superficialis (FDS), flexor carpi ulnaris (FCU), and
flexor carpi radialis (FCR) muscles were used for injections.
Muscles samples were obtained 2 or 8 weeks after the intramuscular injections. Muscles were obtained immediately,
snap-frozen in liquid nitrogen–cooled isopentane, and stored
at - 80C for immunohistochemistry and western blotting.
Skeletal muscle tissues were cut and collected in microtubes
and snap-frozen in liquid nitrogen for RT-PCR analysis.

Antibodies. The following monoclonal antibodies were
used for immunofluorescence: anti-dystrophin DYS-1 (Novocastra, Newcastle upon Tyne, UK). Alexa 488, or Alexa 594
conjugated goat anti mouse secondary antibodies (Invitrogen).
Immunofluorescence. Cryosections
(7.5 mm)
were
blocked with 20% goat serum in phosphate buffered saline,
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FIG. 1. Antisense chemistry and design of multiple exon skipping for dystrophic dogs. (A) Comparison of antisense oligos.
(B) Schematic design of multi (double) exon skipping therapy for dystrophic dogs. At least two exons (exons 6 and 8) need to
be skipped (removed) with antisense oligos to correct their reading frame. Gua, Guanidine.
and then incubated with a primary antibody at 4C overnight.
Alexa 488, or 594-conjugated anti-mouse goat antibody (Invitrogen, Camarillo, CA) was used as the secondary antibody.
The sections were viewed and photographed by a laser
scanning microscope, FluoViewTM (Olympus, Tokyo, Japan)

The number of positive fibers for DYS-1 was counted and
compared in sections containing the largest number of positive fibers as described previously (Yokota et al., 2006). At
least 200 muscle fibers were counted in each section for the
analysis.

Table 1. Antisense Oligo Sequences

Table 2. Additional Antisense
Oligo Sequences for Exon 8

Oligo name
Ex6A
Ex6B
Ex8A

Sequence (5¢–3¢)
GTTGATTGTCGGACCCAGCTCAGG
ACCTATGACTGTGGATGAGAGCGTT
CTTCCTGGATGGCTTCAATGCTCAC

Oligo name
Ex8G
Ex8I
Ex8K

Sequence (5¢–3¢)
GGCAAAACTTGGAAGAGTGATGTGA
CCTTGGCAACATTTCCACTTCCTGG
TTTACCTGTTGAGAATAGTGCATTT

VIVO-MORPHOLINO EXON SKIPPING IN CXMD DOGS
Western blotting analysis
Muscle proteins from cryosections were extracted with lysis buffer containing 75 mM Tris-HCl (pH 6.8), 10% sodium
dodecyl sulfate, 10 mM EDTA, and 5% 2-mercaptoethanol.
Four to 40 mg proteins were loaded onto precase 3%–8% resolving sodium dodecyl sulfate polyacrylamide gel electro-
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phoresis gels following manufacturer’s instructions (Bio-Rad,
Hercules, CA). The gels were transferred by semidry blotting
at 400 mA for 1.5 hours. DYS-1 (Novocastra) antibody against
dystrophin and rabbit polyclonal antibody against desmin
(Abcam) were used as primary antibodies. Horseradish
peroxidase–conjugated anti-mouse or anti-rabbit goat immunoglobulin (Cedarlane Laboratories, Hornby, Ontario,

FIG. 2. Vivo phosphorodiamidate morpholino oligomer (vPMO) local injections restore dystrophin expression in TA 8 weeks
later. (A) Immunohistochemistry with dystrophin (DYS1) antibody 8 weeks after the cocktail vPMO treatment containing Ex6A,
Ex6B, and Ex8A in canine X-linked muscular dystrophy (CXMD) (1.2 mg in total as a cocktail, 400 mg of each oligo), and
unmodified morpholino treatment containing Ex6A, Ex6B, and Ex8A in CXMD (3.6 mg in total as a cocktail, 1.2 mg of each oligo).
(B) The number of dystrophin positive fibers 2 weeks after injections. (C) The number of dystrophin positive fibers 8 weeks after
injections. Scale bar = 200 mm; n = 2–4 in each group; *P < 0.05 compared with non-treated control group.
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(McClorey et al., 2006; Yokota et al., 2009a). Initially, we
employed a cocktail oligo with the same sequences and
combinations, Ex6A, Ex6B, and Ex8A, as previously used
(Yokota et al., 2009a) (Table 1). We compared the efficacy of
exon skipping by vPMOs and unmodified morpholinos.
Sustained dystrophin expression after cocktail
vPMO injections

FIG. 3. Prolonged dystrophin expression after vPMO injections. Western blotting analysis on dystrophin expression
with DYS-1 antibody 8 weeks after vPMO cocktail injections
(120 mg each or 400 mg each of Ex6A, Ex6B, and Ex8A) into
TA muscles in dystrophic dogs as indicated.
Canada) was used as a secondary antibody. Enzyme chemiluminescence kit (GE, Fairfield, CT) was used for the detection. Blots were analyzed by ImageJ software (Collins, 2007).
Reverse transcriptase polymerase chain reaction
Total RNA was extracted from frozen tissue sections using
TRIzol (Invitrogen). Then RT-PCR was performed on 200 ng
of total RNA for 35 cycles of amplification using One-Step RTPCR kit (Qiagen, Chatsworth, CA) following manufacturer’s
instructions with 0.6 mM of an exon 5 (CTGACTCTTGGTTTGATTTGGA) forward primer. Reverse primers were exon 10
(TGCTTCGGTCTCTGTCAATG).
Statistical analysis
The data between samples were compared using F-test and
Student’s or Welch’s t-test. P < 0.05 was considered statistically significant.
Results
Design of antisense vivo-morpholinos
In this study, we employed a cocktail of antisense vivomorpholino oligos (Gene-tools) to induce exon skipping of
exon 6 and exon 8 in the canine dystrophin (DMD) gene (Fig.
1A). A vivo-morpholino is comprised of a morpholino oligo
with a covalently linked delivery moiety, an octa-guanidine
dendrimer. As previously demonstrated, at least two exons
(exon 6 and exon 8) need to be removed to restore the reading
frame of the splice site mutation in the CXMD (Fig. 1B)

FIG. 4. Schematic outline of the antisense morpholinos targeting exon 8
of dog and human dystrophin mRNA.
Antisense oligos against exon 8 of human/dog DMD gene used in this
study. These 4 oligos were previously
reported to be effective for exon 8
skipping in myotubes of dystrophic
dogs and human patients in vitro (Saito
et al., 2010).

Since sustained recovery of dystrophin expression was
previously reported after vivo-morpholino injections into
dystrophic mdx mice, we tested the dystrophin expression
levels 2 weeks and 8 weeks after vPMO injections in cranial
tibialis (tibialis anterior in humans) muscles in dystrophic
dogs (Fig. 2) ( Jearawiriyapaisarn et al., 2008; Wu et al., 2009;
Widrick et al., 2011; Wu et al., 2011a). In this study, we employed 3- to 5-month-old dystrophic dogs. At this stage the
disease progression was relatively mild in these dogs. We
employed a cocktail of three antisense oligos named Ex6A,
Ex6B, and Ex8A (Table 1). We used anti-rod domain dystrophin antibody because anti-C-terminus dystrophin antibodies
cross-react with other dystrophin isoforms (e.g., Dp71).
While unmodified PMO (1.2 mg each, or 3.6 mg in total as a
cocktail) injected muscle showed almost no detectable dystrophin expression 8 weeks after injections, extensive dystrophin
expression was observed after 400 mg vPMO injected muscles
(Fig. 2A). At 2 weeks after the vPMO (400 mg each) injection,
approximately 75% of fibers were positive with dystrophin
DYS-1 antibody, while 55% were positive after unmodified
PMO injection (1.2 mg each) (Fig. 2B). A cocktail of antisense
vPMOs was required to induce dystrophin expression (Fig.2B).
Injections with single antisense vPMO targeting exon 6 only
(Ex6A) did not induce detectable level of dystrophin expression
(Fig. 2B). At 8 weeks after vPMO injection, approximately 60%
of fibers were still positive with DYS-1 antibody, while only
10% were positive after unmodified PMO injection (Fig. 2C).
The expression level of dystrophin was then examined by
western blotting analysis (Fig. 3). Approximately 20% of
the level of dystrophin in wild-type was detected in vPMOinjected muscles 8 weeks after the injection with 400 mg each of
Ex6A, Exx6B, and Ex8A (or 1.2 mg in total as a cocktail).
Design of novel antisense sequences and combinations
for dystrophin exon 8
Next, to further optimize the antisense oligo sequences and
combinations, we tested new oligos named Ex8G, Ex8I, and
Ex8K (Fig. 4, Table 2). In previous study, these oligos
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FIG. 5. A 4-oligo cocktail containing
Ex8G induces efficient dystrophin expression. Detection of exon 6–9 skipped band with reverse-transcription
polymerase chain reaction analysis.
Equal amounts (120 mg) of oligos in
total were injected into indicated
muscles (i.e., 40 mg each in three-oligo
cocktails, 30 mg each in four-oligo
cocktails). FCR, flexor carpi radialis;
FDS, flexor digitorum superficialis;
FCU, flexor carpi ulnaris.

efficiently induced exon 8 skipping in vitro in dog and human
myotubes (Saito et al., 2010). These oligos were designed to
target exon/intron borders or exonic splice enhancer (ESE)
sites. ESE scores were obtained by using ESE finder software
(Cartegni et al., 2003). These oligos target the same conserved
sequences in both dog and human dystrophin mRNA.
A novel antisense cocktail induces more efficient
exon 8 skipping
We tested the efficacy of newly designed oligos by intramuscular injections into skeletal muscles in dystrophic dogs
(Fig. 5). We previously reported a cocktail oligo containing
Ex6A, Ex6B, Ex8A, and Ex8G led to the most efficient double
exon skipping of exon 6–8 (or triple skipping of exon 6–9) in both
human and dog myotubes in vitro (Saito et al., 2010). Exon 9 was
not targeted by antisense oligos but the exon is known as an
alternative splice site which is spontaneously skipped with exon
6–8 skipping induced by antisense oligos in previous studies
(Reiss and Rininsland 1994; McClorey et al., 2006). Here, we
compared the efficacy of multiple exon skipping induced by the
three oligos cocktail which we have previously reported effective for systemic trials in dystrophic dogs (Yokota et al., 2009a),
and newly designed 4-oligo cocktails, which we found to be
more effective in vitro (Saito et al., 2010). Here, 3-oligo cocktail
oligos (Ex6A + Ex6B + Ex8A) were injected into right-side
muscles of flexor carpi radialis (FCR), Flexor digitorum superficialis (FDS), or flexor carpi ulnaris (FCU) as controls. Different
combinations of 4-oligo cocktails were injected into contralateral
(left side) muscles (Fig. 5). The same total doses (120 mg) of 3oligo cocktails or of 4-oligo cocktails were injected (i.e., 40 mg
each in 3-oligo cocktails, and 30 mg each in 4-oligo cocktails). The
efficacy of multiple exon skipping was initially examined by RTPCR analysis. While all combinations led to substantial amount
of exon 6–9 skipped in-frame mRNA products, the highest efficacy was achieved with the 4-oligo cocktail containing Ex8G
(Ex6A + Ex6B + Ex8A + Ex8G), which is consistent with our
previous report in myotubes in vitro (Saito et al., 2010).
Efficient dystrophin recovery after injections
with four-oligo cocktail vPMOs
Next, we examined the recovery of dystrophin expression
by immunohistochemistry with DYS-1 anti-dystrophin

monoclonal antibody 2 weeks after intramuscular vPMO injections (Fig. 6). Although all tested cocktail oligos induced
extensive expression of dystrophin, the highest recovery was
obtained with the 4-oligo cocktail containing Ex6A, Ex6B,
Ex8A, and Ex8G (Fig. 6). Approximately 70 percent of fibers
was positively stained with the four-oligo cocktail (Fig. 6B).
The expression levels of dystrophin after cocktail vPMO
injections were also compared with western blotting analysis
(Fig. 7). Desmin antibody was used as an internal control.
Again, the 4-oligo cocktail injection with Ex6A, Ex6B, Ex8A,
and Ex8G led to the highest levels of dystrophin expression.
Discussion
Antisense mediated exon skipping is currently a most
promising therapeutic approach to curing DMD (Yokota
et al., 2007b; Hoffman et al., 2011; Partridge 2011; Pichavant
et al., 2011). Although phase-2/3 clinical trials are currently
underway, there are a couple of challenges. One of the most
significant challenges is that the effect usually wears off after
3–4 weeks, thus repeated injections are required. Currently,
weekly or bi-weekly injections are required for antisense
systemic trials (Lu et al., 2005; Alter et al., 2006; Wu et al.,
2011b). New generation morpholinos with cell-penetrating
moiety, such as PPMOs and vPMOs, were developed to improve the efficacy in vivo (Moulton and Jiang 2009; Yokota
et al., 2009b). Both PPMOs and vPMOs have the same backbones as conventional unmodified morpholinos (Fig. 1). In
vPMOs, cell-penetrating octa-guanidine dendrimers are conjugated, while in PPMOs, arginine rich polypeptides are
conjugated (Morcos et al., 2008). Peptide-morpholino conjugates (PPMOs) restored dystrophin to more than 80 percent of
wild-type levels in skeletal muscles of mdx mice 9 weeks after
injections, showing prolonged activity (Moulton et al., 2009).
An injection with vPMOs in hDMD mice, a transgenic model
carrying the full-length human dystrophin gene, led to more
than 70% efficiency of targeted human dystrophin exon
skipping in vivo systemically (Wu et al., 2011a). Therefore, use
of morpholino conjugates such as PPMOs or vPMOs might be
able to reduce the frequency of injections.
In this study, we demonstrated the first successful rescue of
dystrophin expression with morpholino conjugates in dystrophic dogs. In previous in vitro experiments, we used a total
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FIG. 6. Immunohistochemistry shows four-oligo cocktails induce efficient dystrophin expression in vivo. (A) Immunohistochemistry with anti-dystrophin antibody (DYS-1; red) and DAPI nuclei staining (blue). Equal amounts (120 mg) of
oligos in total were injected into indicated muscles (i.e., 40 mg each in 3-oligo cocktails, 30 mg each in 4-oligo cocktails). Scale
bars = 200 mm. (B) The percentage of dystrophin positive fibers after cocktail oligo injections.

of 30 mM for 3 or 4 sequences of PMOs (Saito et al., 2010). In
this study, we employed 120mg–1.2 mg of vPMOs for intramuscular injections. The induction of exon 6–9 multiple
skipping mediated by cocktail vPMOs was significantly more
efficient than that mediated by unconjugated PMOs (Fig. 2).
The expression levels were remained very high (60% dystrophin-positive fibers) 2 months after the injection, indicating
prolonged persistence (Figs. 2–3). We employed dogs in early
stages of the disease, because muscle fibers are replaced by
fibrous connective tissue at later stages. This might be generalized to the antisense drug products intended for use in the
first-in-human trial. Importantly, a vPMO cocktail efficiently
rescued other genetic disorders including the mutation in

Fukuyama congenital muscular dystrophy (Taniguchi-Ikeda
et al., 2011). These studies clearly indicate that morpholino
conjugates are not only useful tools for gene-knockdown
study, but also have great potential for treating genetic
disorders.
We next compared newly designed antisense oligos against
exon 8 of dystrophin mRNA in vivo (Figs. 5–7). In accordance
with the previous study in vitro by Saito et al., the most efficient vPMO cocktail was a 2 oligo cocktail containing Ex8A
and Ex8G (Saito et al., 2010). Since exon 6, 7, and 8 are all
among the most prevalent targets of exon skipping therapy
outside the deletion mutation hotspot (exon 45–55), optimization of antisense oligos against these exons is very
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FIG. 7. Restoration of dystrophin expression with f4-oligo cocktail vPMOs. Western blotting analysis with anti-dystrophin
(DYS-1) antibody 2 weeks after vPMO injections. Equal amounts (120 mg) of oligos in total were injected into indicated
muscles (i.e., 40 mg each in 3-oligo cocktails, 30 mg each in 4-oligo cocktails). The 4-oligo cocktail (Ex6A + Ex6B + Ex8A +
Ex8G) leads to the highest level of dystrophin expression. TA, tibialis anterior; EDL, extensor digitorum longus; ECU,
extensor carpi ulnaris.

important. In fact, approximately 3.0% of DMD patients can be
treated with double skipping of exon 6 and exon 7 (ranked No.
9), and 2.3% can be treated with skipping exon 8 (ranked No. 10)
(Aartsma-Rus et al., 2009). Because the exon-skipping approach
is fundamentally a mutation-specific personalized medicine, an
effective path of drug approval process will be also a key to
rescue mutations with a relatively small number of patients.
A major concern of new generation morpholino-mediated
antisense therapy is their toxicity. No toxicity of vPMOs
has been recorded up to 12 mg/kg of systemic injections in
mice (Wu et al., 2009). However, with PPMOs, a high dose
(150 mg/kg) of systemic injections led to adverse events such
as lethargy, weight loss, elevated blood urea nitrogen, and
serum creatinine levels (Amantana et al., 2007). In addition, a
test in the cynomolgus monkey revealed mild tubular degeneration in the kidneys after weekly injections with 9 mg/
kg PPMOs (Moulton and Moulton, 2010). Although AVI5038, a PPMO targeting exon 50 of dystrophin mRNA, is in
preclinical development, the toxicity of PPMOs might pose a
challenge for determination of an effective and safe regimen in
man. An immune suppression regimen such as one used for
robust adeno-associated virus expression might be effective
for systemic trials (Shin et al., 2012; Wang et al., 2007). To test
the systemic effect of vPMOs in dogs, precise pharmacokinetics, biodistribution, stability, and toxicity remain to be
done. Nevertheless, our results indicate clear potential of the
morpholino conjugate as a therapeutic agent to treat DMD
and other genetic disorders.
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